RANCHO MIRAGE, Calif. -- The Census Bureau expects to issue proposed rules for routed export transactions by the fall, said Omari Wooden, assistant division chief, International Trade Management Division at Census. Census is in the process of going through many issues raised by industry in comments to the agency, Wooden said at the National Customs Brokers & Forwarders Association of America's annual conference on May 1. "We are the government, so instead of months, we give you seasons, so probably sometime in the fall we're hopeful to come out with something," he said.
The following lawsuits were filed at the Court of International Trade during the week of April 23-29:
International Trade Today is providing readers with some of the top stories for April 23-27 in case they were missed.
Life Sciences Trade Alert is providing readers with some of the top stories for April 23-27 in case they were missed.
A recent set of court challenges to CBP’s country of origin treatment for pharmaceuticals will proceed as a consolidated “test case,” according to recent filings at the Court of International Trade. Acetris had filed the set of 11 cases in March, contesting CBP’s determination that the Indian active pharmaceutical ingredients in its U.S.-made pharmaceuticals determined the finished drugs’ country of origin, despite a purportedly complex production process in the U.S. and the unsuitability of the raw APIs for use as pharmaceuticals (see 1804030065). The fate of all 11 of those cases will now be decided under a single challenge on the country of origin of Acetris’ rosuvastatin calcium tablets. Other rulings challenged by Acetris involved simvastatin tablets, donepezil hydrochloride tablets, montelukast sodium tablets, paroxetine hydrochloride tablets, carvedilol tablets, metoprolol tartrate tablets, gabapentin capsules, lavetiracetam tablets, levofloxacin tablets and entecavir tablets.
CBP is unjustifiably holding up regulatory changes for drawback required by the Trade Facilitation and Trade Enforcement Act of 2015 by including them in a 450-page regulatory package that may take years to wind through the rulemaking process, said several companies challenging CBP’s interim drawback procedures at the Court of International Trade in a recent legal brief. Responding to the government’s motion to dismiss their case, the plaintiffs said part of the reason CBP hasn’t yet issued its new drawback calculation rules is likely because its upcoming Part 190 proposal includes non-urgent, optional conforming regulations that go beyond Congress’ mandate.
CBP is unjustifiably holding up regulatory changes for drawback required by the Trade Facilitation and Trade Enforcement Act of 2015 by including them in a 450-page regulatory package that may take years to wind through the rulemaking process, said several companies challenging CBP’s interim drawback procedures at the Court of International Trade in a recent legal brief. Responding to the government’s motion to dismiss their case, the plaintiffs said part of the reason CBP hasn’t yet issued its new drawback calculation rules is likely because its upcoming Part 190 proposal includes non-urgent, optional conforming regulations that go beyond Congress’ mandate.
Congress should update the Committee on Foreign Investment in the United States national security mandate to review foreign investments in U.S.-located companies, lawmakers and witnesses said at a House Digital Commerce Subcommittee hearing Thursday. There were differences over details of the administration-backed Foreign Investment Risk Review Modernization Act's (FIRRMA, HR-4311/S-2098) proposed CFIUS expansion to probe more investments, including in "critical" technology or infrastructure companies. Some said CFIUS should also examine key economic issues. CFIUS is chaired by the Department of Treasury and includes eight other executive branch departments and offices (five others have observer status and participate as appropriate).
Congress should update the Committee on Foreign Investment in the United States national security mandate to review foreign investments in U.S.-located companies, lawmakers and witnesses said at a House Digital Commerce Subcommittee hearing Thursday. There were differences over details of the administration-backed Foreign Investment Risk Review Modernization Act's (FIRRMA, HR-4311/S-2098) proposed CFIUS expansion to probe more investments, including in "critical" technology or infrastructure companies. Some said CFIUS should also examine key economic issues. CFIUS is chaired by the Department of Treasury and includes eight other executive branch departments and offices (five others have observer status and participate as appropriate).
The China Chamber of International Commerce opposes the Trump administration’s imposition of 25 percent tariffs on Chinese imports (see 1803230016) and wants to send delegates from Beijing to the U.S. Trade Representative’s May 15 hearing to testify to that effect, it commented, in a filing posted Wednesday in docket USTR-2018-0005. “None of the public comments submitted by interested parties has identified any Chinese laws or regulations that mandatorily requires technology transfer, or present any real and concrete case in which the Chinese government has in practice forced transfer of technologies.”